Remedium Technologies Inc., a medical device company developing innovative products to control severe hemorrhaging, was awarded a $500,000 Small Business Innovation Research (SBIR) grant from the National Science Foundation to test the company’s sprayable foam for rapidly halting traumatic bleeding, company officials announce today.
In collaboration with Massachusetts General Hospital and the University of Maryland, Remedium will complete pre-clinical trials to evaluate the safety and efficacy of Hemogrip(TM) Foam in controlling non-compressible hemorrhaging, i.e., bleeding not accessible to direct pressure. Hemogrip(TM) is a high-pressure, sprayable foam that can expand into an injured body cavity, adhere to tissue and stop hemorrhaging within minutes during the expansion process. There are currently no hemostatic products available for treatment of non-compressible bleeds, which account for 85 percent of hemorrhage-related deaths.